1.25
Finanzdaten der Alzamend Neuro Inc-Aktie (ALZN)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
| Enddatum des Zeitraums | 2026-07-31 | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 |
| Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
| Operating Expenses |
5.38%
3.0254
|
2.8709 | 2.1977 | 0.9981 | 2.7002 |
| Interest Income/Expense |
1,237%
0.00201
|
0.00015 | 0.00134 | 0.00265 | 0.00248 |
| Operating Income/Loss |
5.38%
-3.0254
|
-2.8709 | -2.1977 | -0.9981 | -2.7002 |
| Nonoperating Income/Loss |
273.06%
-0.00161
|
0.000928 | -0.00134 | -0.00265 | -0.00248 |
|
|
120.59%
-3.027
|
14.70 | -2.199 | -1.0008 | 2.70 |
| Basic Average Shares |
4.4787
|
- | 3.8047 | 3.381 | 2.106 |
| Diluted Average Shares |
4.4787
|
- | 3.8047 | 3.381 | 2.106 |
| Basic Earnings Per Share |
-0.68
|
- | -0.58 | -0.30 | -1.28 |
| Diluted Earnings Per Share |
-0.68
|
- | -0.58 | -0.30 | -1.28 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):